Biotech

All Articles

Actinogen's cortisol blocker stops working period 2 anxiety study

.Actinogen Medical's cortisol blocker has actually missed the primary endpoint of a phase 2 research...

Bivictrix decides going personal only means to take ADC in to clinic

.Antibody-drug conjugates (ADCs) have actually gone to the facility of a lot of a billion-dollar bio...

TPG tops up funds to $580M for financial investments throughout life scientific researches

.Possession manager TPG, which has supported biotechs including Sionna Rehabs as well as Santa Clam ...

Merck quits period 3 TIGIT trial in bronchi cancer for impossibility

.Merck &amp Co.'s TIGIT system has actually suffered yet another setback. Months after shuttering a ...

After a challenging year, Exscientia folds up into Recursion

.After a year determined through pipeline hairstyles, the variation of its chief executive officer a...

Cullinan, after $25M package, restore bispecific to Harbour

.Cullinan Rehab was made an impression on enough with Harbour BioMed's bispecific immune activator t...

A better consider Intense Biotech's Intense 15

.In this full week's episode of "The Top Line," our team're diving right into Tough Biotech's annual...

Lilly deals with phase 2 breakdown of tau-targeting med

.The confetti is actually still flying coming from Eli Lilly's gathering commemorating the approval ...

Biogen CMO Maha Radhakrishnan participates in Sofinnova-- Chutes &amp Ladders

.Welcome to today's Chutes &amp Ladders, our roundup of significant leadership hirings, shootings an...

Lykos are going to talk to FDA to reconsider its choice following being rejected of MDMA therapy for trauma

.Adhering to an unsatisfactory showing for Lykos Therapeutics' MDMA prospect for post-traumatic stre...